GlassScriptPhysician profile
Melissa A Chiarelli
NPI 1356442826
$3,352.40
in general payments reported to CMS, 2019-2025
26 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.55 · 2021: $217 · 2022: $407 · 2023: $630 · 2024: $972 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,715.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $720.18 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $323.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $311.62 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $292.11 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $289.23 | 2022-2025 | |
| Lilly USA, LLC | $249.76 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.28 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.03 | 2021-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $149.14 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $118.59 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Abbott Laboratories | $109.53 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $62.35 | 2024-2025 | Rexulti |
| Daiichi Sankyo INC. | $54.95 | 2022-2023 | Injectafer |
| Amgen INC. | $51.30 | 2021-2025 | Otezla, Repatha, Prolia |
| Medtronic, INC. | $32.65 | 2024 | Linq II |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.44 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $31.74 | 2020-2023 | |
| Sanofi Pasteur INC. | $25.10 | 2024 | |
| Inspire Medical Systems, INC. | $24.55 | 2025 | Inspire |
| Dexcom, INC. | $22.71 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $21.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.32 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.02 | 2025 | Camzyos |
| Seqirus USA INC | $16.46 | 2024 | Flucelvax, Fluad |
| Janssen Pharmaceuticals, INC | $16.29 | 2022 | |
| Bausch Health US, LLC | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Chiarelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.